# Technical Accuracy Review

**Paper:** "The Blind Spots of Agentic Drug Discovery"
**Reviewer Role:** Technical Accuracy Verification
**Date:** 2026-02-06

---

## Methodology

Every verifiable technical claim in the manuscript was identified and checked via web search against published literature, official documentation, and authoritative sources. Claims are organized by category and assessed as: **Accurate**, **Partially Accurate**, **Inaccurate**, or **Unverifiable**.

---

## A) Protein Language Models

### Claim 1: ESM-2 embeddings predict receptor types from sequence alone (Section 2)
- **Verdict: Accurate**
- ESM-2 (Lin et al., Science, 2023) is trained on ~65 million unique sequences and produces embeddings that encode evolutionary and structural priors. The model has been widely used for downstream classification tasks from sequence alone, including contact prediction and structure inference. The claim that embeddings can predict receptor types is a valid downstream application.

### Claim 2: ProtBERT fine-tuning enables transfer learning with fewer than 100 examples (Section 2)
- **Verdict: Partially Accurate**
- ProtBERT/ProtTrans (Elnaggar et al., IEEE TPAMI, 2022) does enable transfer learning. Research confirms that fine-tuning protein language models is effective on small datasets. However, the specific claim "fewer than 100 examples" is not directly backed by a citation. While plausible (and supported by general PLM fine-tuning literature showing task-specific improvements on small datasets, especially with parameter-efficient methods like LoRA), the paper would benefit from a citation supporting this specific threshold or softening to "on the order of hundreds of examples."

### Claim 3: ProGen encodes evolutionary and structural priors from millions of protein sequences (Section 2)
- **Verdict: Accurate**
- ProGen (Madani et al., Nature Biotechnology, 2023) is a 1.2 billion-parameter model trained on 280 million protein sequences from >19,000 families. It generated functional proteins (lysozymes) with as low as 31.4% identity to natural proteins.

### Claim 4: ProtGPT2 fine-tunes on therapeutic sequences for de novo generation (Section 2)
- **Verdict: Accurate**
- ProtGPT2 (Ferruz et al., Nature Communications, 2022) is a deep unsupervised language model for protein design that generates de novo sequences following natural principles. 88% of generated proteins are predicted globular. The claim about fine-tuning on therapeutic sequences is a valid application of the model.

### Claim 5: RL optimization of generative models requires reward models, policy networks, gradients, and KL regularization (Section 2)
- **Verdict: Accurate**
- GRPO (Group Relative Policy Optimization) and related RL methods for protein generation explicitly use KL divergence constraints, reward functions, and policy optimization. ProteinZero (2025) and ProtRL confirm these are standard components. The technical description is sound.

---

## B) Agent Systems

### Claim 6: ChemCrow orchestrates 18 chemistry tools (Section 1)
- **Verdict: Accurate**
- ChemCrow (Bran et al., Nature Machine Intelligence, 2024; arXiv preprint April 2023) integrates exactly 18 expert-designed tools including RDKit, PubChem, and reaction prediction APIs. The description is correct.

### Claim 7: ChatInvent completed a 13-month deployment at AstraZeneca for literature synthesis (Section 1)
- **Verdict: Partially Accurate / Unverifiable**
- He et al. (Drug Discovery Today, 2026) describes ChatInvent at AstraZeneca. The system evolved from a proof-of-concept single agent to a multi-agent architecture for molecular design and synthesis planning. However, the specific "13-month deployment" claim could not be verified from search results. More importantly, the paper describes ChatInvent as focused on "molecular design and synthesis planning," not primarily "literature synthesis" as the manuscript states. **Recommendation:** Verify the 13-month timeframe from the original paper. Also consider revising "literature synthesis" to "molecular design and synthesis planning" or "literature-informed molecular design" if the original paper's scope is broader than pure literature mining.

### Claim 8: Coscientist autonomously plans chemical syntheses (Section 1)
- **Verdict: Accurate**
- Coscientist (Boiko et al., Nature, 2023) autonomously designs, plans, and performs complex experiments. It planned synthesis procedures for seven molecules (including aspirin and ibuprofen) and executed Sonogashira and Suzuki-Miyaura cross-coupling reactions. The description is correct.

### Claim 9: PharmAgents integrates knowledge graphs for target identification (Section 1)
- **Verdict: Accurate**
- PharmAgents (Gao et al., arXiv, March 2025) decomposes drug discovery into four stages: target discovery, lead identification, lead optimization, and preclinical evaluation, with specialized LLM-based agents. The target discovery module identifies disease-relevant protein targets. The "knowledge graphs" characterization is consistent with the multi-source knowledge integration described.

### Claim 10: PharmAgents assumes rigid-body docking, inappropriate for flexible peptides (Section 2)
- **Verdict: Partially Accurate / Unverifiable**
- PharmAgents does focus on structure-based drug design for small molecules. However, a specific claim that it "assumes rigid-body docking" could not be directly verified from the paper's abstract/description. The general point that it is not designed for flexible peptide docking is reasonable given its small-molecule focus, but the specific "rigid-body docking" characterization should be verified against the original paper. **Recommendation:** Soften to "PharmAgents focuses on small-molecule structure-based design workflows, inappropriate for flexible peptide interactions" unless rigid-body docking is explicitly confirmed.

### Claim 11: ChatInvent mines small-molecule synthesis routes, irrelevant to peptide synthesis (Section 2)
- **Verdict: Partially Accurate**
- ChatInvent focuses on molecular design and synthesis planning in a small-molecule context at AstraZeneca. The claim that its synthesis route planning is irrelevant to peptides is reasonable since peptide synthesis (SPPS) follows fundamentally different workflows. However, characterizing ChatInvent as only "mining synthesis routes" may understate its molecular design capabilities.

### Claim 12: TxGemma provides therapeutics-focused language understanding (Section 1)
- **Verdict: Accurate**
- TxGemma (Wang et al., arXiv, April 2025) is a suite of 2B, 9B, and 27B parameter models fine-tuned from Gemma-2 for therapeutic property prediction across 66 tasks involving small molecules, proteins, nucleic acids, diseases, and cell lines. The description is correct.

### Claim 13: BioPlanner benchmarks LLM-driven protocol planning (Section 4)
- **Verdict: Accurate**
- BioPlanner (O'Donoghue et al., EMNLP 2023) presents an automatic evaluation framework for LLM protocol planning in biology. The BioProt dataset of protocols with pseudocode was used to evaluate GPT-3 and GPT-4. The description is accurate.

### Claim 14: ChemToolAgent evaluates chemistry tool integration (Section 4)
- **Verdict: Accurate**
- ChemToolAgent (Yu et al., NAACL 2025 Findings; arXiv November 2024) evaluates the impact of tools on language agents for chemistry problem solving. It found that tool augmentation does not consistently outperform base LLMs, particularly for general chemistry reasoning. The characterization is fair.

### Claim 15: MADD coordinates molecular design and docking (Section 4)
- **Verdict: Accurate**
- MADD (Solovev et al., EMNLP 2025 Findings; arXiv November 2025) uses four coordinated agents to build and execute hit identification pipelines from natural language queries, achieving 79.8% pipeline accuracy. The description is accurate.

### Claim 16: DiscoVerse promises multi-agent collaboration (Section 1)
- **Verdict: Accurate**
- DiscoVerse (Zheng et al., arXiv November 2025) is a multi-agent pharmaceutical co-scientist from Roche-affiliated researchers for traceable drug discovery and reverse translation. It focuses on semantic retrieval, cross-document linking, and auditable synthesis on Roche's historical corpus. The description is accurate.

### Claim 17: Seal et al. is a "20-author comprehensive technical survey (45 pages, 12 figures)" (CLAUDE.md context)
- **Verdict: Partially Accurate**
- The paper has 20 authors (Srijit Seal + 19 others), confirmed. It is described as a comprehensive survey. However, the "45 pages, 12 figures" claim could not be precisely verified via web search alone. The paper is described as comprehensive and extensive. **Recommendation:** Verify page/figure count from the PDF directly. This claim does not appear in the manuscript itself, only in the project context file, so it is low priority.

---

## C) ML/RL Methods

### Claim 18: NSGA-II maintains candidate populations and selects non-dominated solutions (Section 6)
- **Verdict: Accurate**
- NSGA-II (Non-dominated Sorting Genetic Algorithm II) is a well-established multi-objective evolutionary algorithm. It maintains populations, performs fast non-dominated sorting, and uses crowding distance for diversity preservation. The characterization is technically sound. NSGA-II has been applied in drug discovery for optimizing QED, synthetic accessibility, and docking scores.

### Claim 19: Multi-objective Bayesian optimization models objectives, selects candidates via acquisition functions balancing exploration and Pareto improvement (Section 6)
- **Verdict: Accurate**
- Bayesian optimization with Gaussian processes uses acquisition functions (Expected Improvement, Upper Confidence Bound) to balance exploitation and exploration. Multi-objective extensions exist for Pareto-based optimization. The description is technically correct.

### Claim 20: Active learning reduced assays by 30-40% (Section 5, citing Reker 2017)
- **Verdict: Partially Accurate / Unverifiable**
- Reker et al. (Future Medicinal Chemistry, 2017) discusses active learning for computational chemogenomics. The general principle that active learning reduces experimental burden is well-established (e.g., discovering 60% of synergistic drug pairs with only 10% combinatorial exploration). However, the specific "30-40%" reduction figure could not be verified from search results about the Reker 2017 paper. The manuscript later says "active learning reduced assays by one-third" (also attributed to practitioner experience, not the citation). **Recommendation:** Clarify whether the 30-40% figure comes from Reker 2017 or from the author's own experience. If from personal experience, do not cite Reker 2017 for this specific statistic. If from the literature, provide the correct citation.

### Claim 21: GRPO variants with curriculum learning, diversity-aware rewards, KL regularization (Section 2)
- **Verdict: Accurate**
- GRPO supports dynamic reward functions including curriculum learning. KL divergence regularization is a standard component (confirmed by HuggingFace TRL documentation and ProteinZero). Diversity penalties for avoiding mode collapse are standard practice in protein generation RL. The technical description is sound.

### Claim 22: Few-shot learning with prototypical networks achieved 60-70% accuracy on peptide-receptor binding with only 20 examples per type (Section 5)
- **Verdict: Unverifiable**
- This appears to be a practitioner experience claim. Prototypical networks are a valid metric-based meta-learning approach. The claimed performance (60-70% accuracy with 20 examples) is plausible for few-shot protein classification but cannot be verified externally. This is acceptable as a practitioner anecdote if framed accordingly. **Recommendation:** Ensure this is clearly framed as practitioner experience, not a literature claim.

---

## D) Pareto Optimization

### Claim 23: A candidate is Pareto-optimal if no other improves one objective without degrading another (Section 6)
- **Verdict: Accurate**
- This is the standard textbook definition of Pareto optimality/efficiency. Correctly stated.

### Claim 24: The Pareto frontier is a curve (two objectives) or surface (three+) (Section 6)
- **Verdict: Accurate**
- Correct geometric characterization. In two-objective space, the Pareto front forms a curve; in three or more objectives, it forms a surface (or hypersurface). Standard multi-objective optimization theory.

### Claim 25: Steep regions of the frontier require large sacrifices for modest gains; flat regions allow improvements with minimal cost (Section 6)
- **Verdict: Accurate**
- This is a correct interpretation of the trade-off structure along a Pareto frontier. The marginal rate of substitution varies along the frontier, and this geometric interpretation is standard.

### Claim 26: Agents optimize single objectives or collapse to weighted sums like "0.6 x bioactivity + 0.4 x drug-likeness" (Section 6)
- **Verdict: Accurate**
- ChemCrow focuses on individual properties (binding affinity, synthetic accessibility). Coscientist targets synthesis yield. The weighted sum approach is explicitly referenced via Bickerton et al. (2012) QED metric, which combines multiple drug-likeness properties into a single score. The critique that this discards Pareto information is technically valid.

---

## E) Table 1: Small Molecule vs Peptide Comparison

The paper does not contain an explicit Table 1 with a row-by-row comparison, but Section 2 makes several comparative claims:

### Claim 27: Peptides are conformationally flexible, sampling diverse structural states, unlike rigid small molecules (Section 2)
- **Verdict: Accurate**
- Therapeutic peptides (2-50 amino acids) are structurally flexible molecules with conformations that are highly environment-dependent. Small molecules are generally more rigid (though some flexibility exists). The comparison is valid at the level of generality stated.

### Claim 28: Peptides cannot encode as SMILES without losing stereochemistry (Section 2)
- **Verdict: Partially Accurate**
- SMILES can encode stereochemistry via @/@@/@@ notation (e.g., L-Alanine as N[C@@H](C)C(=O)O). However, research confirms significant practical limitations: missed chirality centers, challenges with non-canonical amino acids, and inability to encode conformational stereochemistry (helices, mechanical constraints). The statement is slightly overstated. **Recommendation:** Revise to "Peptides cannot be fully represented as SMILES without risking loss of stereochemical and conformational information" or "SMILES encoding of peptides is error-prone and incomplete, particularly for non-natural amino acids and conformational features."

### Claim 29: Molecular fingerprints (Morgan, MACCS) have no peptide analog (Section 2)
- **Verdict: Partially Accurate**
- Research shows that MACCS keys and Morgan fingerprints perform best for small molecules, while atom-pair fingerprints are preferable for larger molecules such as peptides. No available fingerprint achieves good performance on both classes. While there is no direct "peptide analog" of Morgan/MACCS that is standard, atom-pair fingerprints and PLM embeddings serve analogous roles. The claim is directionally correct but slightly overstated. **Recommendation:** Consider "Standard molecular fingerprints (Morgan, MACCS) perform poorly on peptides, which lack equivalent standard representations" instead of "have no peptide analog."

### Claim 30: Therapeutic peptides are 2 to 50 amino acids bridging small molecules and biologics (Section 2)
- **Verdict: Accurate**
- Confirmed by multiple sources. Therapeutic peptides typically comprise 2 to 50 amino acid residues and bridge the gap between traditional small-molecule drugs and large biologics like monoclonal antibodies.

### Claim 31: Peptides face aggregation, protease degradation, and permeability barriers (Section 2)
- **Verdict: Accurate**
- Well-documented challenges in peptide therapeutics. Protease degradation (short serum half-life), aggregation propensity, and membrane permeability are the three major obstacles to peptide drug development, extensively confirmed in the literature.

---

## F) Table 2: Large Pharma vs Small Biotech Comparison

The paper describes these differences in Section 5:

### Claim 32: Large pharma has millions of tested molecules; small biotech has 50-500 (Section 5)
- **Verdict: Accurate**
- AstraZeneca and similar large pharma companies accumulate compound libraries of millions of molecules over decades. Small biotechs, particularly those focused on peptides, may have only tens to hundreds of proprietary sequences. The magnitude difference is correctly characterized.

### Claim 33: ChatInvent's deployment accessed institutional databases, HPC clusters, and proprietary libraries (Section 5)
- **Verdict: Accurate**
- The He et al. 2026 paper describes a system evolved into a scalable multi-agent architecture at AstraZeneca, which has extensive computational infrastructure, proprietary molecular databases, and institutional knowledge built over decades. This characterization is fair.

### Claim 34: On 100 sequences, deep networks overfit catastrophically (Section 5)
- **Verdict: Accurate**
- This is a well-known phenomenon in ML. Deep neural networks with millions of parameters trained on very small datasets (~100 examples) without appropriate regularization, transfer learning, or data augmentation will overfit. The claim is directionally correct though "catastrophically" may be slightly strong if transfer learning is used.

### Claim 35: ESM-2 pre-trained on millions of protein sequences enables fine-tuning lightweight classifiers on 50-200 examples (Section 5)
- **Verdict: Accurate**
- ESM-2 is trained on millions of sequences. Research confirms that fine-tuning (especially with parameter-efficient methods like LoRA) is effective on small datasets. The specific range of 50-200 examples is plausible and consistent with reported few-shot adaptation results in PLM literature.

---

## G) Other Technical Claims

### Claim 36: DeepLabCut tracks animal poses in videos, generating time-series keypoint coordinates (Section 3)
- **Verdict: Accurate**
- DeepLabCut (Mathis et al., Nature Neuroscience, 2018) performs markerless pose estimation of user-defined body parts using deep learning. It generates time-series keypoint coordinates from video data with human-level accuracy using ~200 labeled frames. The description is correct.

### Claim 37: RNA-seq requires STAR, HISAT2, DESeq2, edgeR, GSEA (Section 3)
- **Verdict: Accurate**
- These are standard bioinformatics tools for RNA-seq analysis. STAR and HISAT2 for alignment, DESeq2 and edgeR for differential expression, and GSEA for gene set enrichment analysis. The pipeline description is accurate and reflects standard practice.

### Claim 38: GSEA maps genes to biological processes via KEGG or Gene Ontology (Section 3)
- **Verdict: Accurate**
- GSEA (Subramanian et al., PNAS, 2005) evaluates gene expression data at the level of gene sets defined by biological knowledge bases. KEGG (Kanehisa et al.) and Gene Ontology are standard pathway databases. The description is correct.

### Claim 39: Stability modifications (D-amino acids, non-natural residues, cyclization) improve half-life but can reduce affinity, increase aggregation, or complicate synthesis (Section 6)
- **Verdict: Accurate**
- D-amino acids confer protease resistance (up to 10^5-fold improvement in stability). Cyclization is a complementary strategy. However, these modifications can indeed affect binding affinity, increase aggregation propensity, or complicate chemical synthesis. This trade-off is well-documented.

### Claim 40: Mouse pharmacokinetics extrapolate to humans via allometric scaling (Section 3)
- **Verdict: Accurate**
- Allometric scaling (Y = aW^b) is a standard empirical approach for cross-species PK extrapolation. It works particularly well for peptides and proteins since biological processes involved in metabolism are evolutionarily conserved. The claim is accurate.

### Claim 41: Peptide stability varies by species protease expression (Section 3)
- **Verdict: Accurate**
- Species-specific differences in protease expression profiles affect peptide stability. Rodent vs. primate protease environments differ, and immunogenicity responses vary by species. This is well-documented in PK/PD literature.

### Claim 42: Workflow orchestration exists: Apache Airflow, Kubeflow, Nextflow (Section 4)
- **Verdict: Accurate**
- All three are established workflow orchestration platforms. Airflow (general-purpose DAG-based), Kubeflow (ML-specific on Kubernetes), and Nextflow (bioinformatics-focused) all provide task graphs, dependency resolution, resource allocation, and checkpointing.

### Claim 43: AlphaFold structure prediction is central to peptide design (Section 2)
- **Verdict: Accurate**
- AlphaFold (Jumper et al., Nature, 2021) and its successor AlphaFold-Multimer have been applied to peptide-protein complex modeling. AF2 can predict peptide-protein interactions with good accuracy (Ca-RMSD < 3.0 A for >50% of test cases). The claim that it is central to modern peptide design is fair.

### Claim 44: Toxicology requires dose-response analysis via generalized linear mixed models accounting for repeated measures and time-dependent effects (Section 3)
- **Verdict: Accurate**
- GLMMs are appropriate for dose-response data with repeated measures. They handle non-normal response variables (binary, ordinal, count), account for autocorrelation in repeated measurements, and model time-dependent effects. The characterization is technically sound.

### Claim 45: Most development cost and risk lies in translating in vitro activity to in vivo efficacy and safety (Section 3, citing DiMasi 2016)
- **Verdict: Accurate**
- DiMasi et al. (Journal of Health Economics, 2016) estimated total capitalized R&D costs at $2.6 billion per approved drug, with clinical phases (which involve in vivo translation) accounting for the majority of costs. The claim is well-supported.

---

## H) Bibliography Accuracy

### Bib entry: he2026chatinvent
- **Verdict: Partially Verifiable** - Drug Discovery Today, January 2026. DOI and PMID provided. The article exists on ScienceDirect. Volume/pages should be verified from the actual article.

### Bib entry: boiko2023coscientist
- **Verdict: Accurate** - Nature, Vol 624, pp 570-578, 2023. Authors confirmed (Boiko, MacKnight, Kline, Gomes). DOI correct.

### Bib entry: bran2024chemcrow
- **Verdict: Accurate** - Nature Machine Intelligence, Vol 6, pp 525-535, 2024. arXiv preprint April 2023. Authors confirmed. DOI correct.

### Bib entry: lin2023esm2
- **Verdict: Accurate** - Science, Vol 379, No 6637, pp 1123-1130, 2023. DOI and PMID correct.

### Bib entry: elnaggar2022protbert
- **Verdict: Accurate** - IEEE TPAMI, Vol 44, No 10, pp 7112-7127, 2022. DOI correct. Note: The title in the bib is "ProtTrans" (the project name), which is the correct full paper title. The manuscript refers to it as "ProtBERT" which is one specific model within the ProtTrans family. This is an acceptable shorthand.

### Bib entry: madani2023progen
- **Verdict: Accurate** - Nature Biotechnology, Vol 41, pp 1099-1106, 2023. DOI correct.

### Bib entry: ferruz2022protgpt2
- **Verdict: Accurate** - Nature Communications, Vol 13, article 4348, 2022. DOI correct.

### Bib entry: stokes2020ml
- **Verdict: Partially Accurate** - Cell, Vol 180, Issue 4. The bib says pages 688-702.e13. Web search confirmed pages as 688-702.e13. However, another source says the issue was 2 and the pages were 475-483. **Recommendation:** Double-check the exact volume/issue/pages from the original publication. The Cell article may have been published online in one issue and in print in another.

### Bib entry: reker2017activelearning
- **Verdict: Accurate** - Future Medicinal Chemistry, Vol 9, No 4, pp 381-402, 2017. Authors confirmed (Reker, Schneider P., Schneider G., Brown J.B.). DOI and PMID correct.

### Bib entry: subramanian2005gsea
- **Verdict: Accurate** - PNAS, Vol 102, No 43, pp 15545-15550, 2005. DOI and PMID correct.

### Bib entry: dimasi2016costs
- **Verdict: Accurate** - Journal of Health Economics, Vol 47, pp 20-33, 2016. DOI and PMID correct.

### Bib entry: bickerton2012qed
- **Verdict: Accurate** - Nature Chemistry, Vol 4, pp 90-98, 2012. Authors and DOI confirmed.

### Bib entry: bioplanner2023
- **Verdict: Accurate** - EMNLP 2023, pp 2676-2694. Authors confirmed. DOI correct.

### Bib entry: madd2025
- **Verdict: Accurate** - EMNLP 2025 Findings, arXiv:2511.08217, November 2025. Confirmed.

### Bib entry: discoverse2025
- **Verdict: Accurate** - arXiv:2511.18259, November 2025. Roche-affiliated researchers confirmed.

### Bib entry: chemtoolagent2024
- **Verdict: Accurate** - NAACL 2025 Findings (accepted), arXiv:2411.07228, November 2024. Authors confirmed.

### Bib entry: txgemma2025
- **Verdict: Accurate** - arXiv:2504.06196, April 2025. Google Research. Authors confirmed.

### Bib entry: seal2025aiagents
- **Verdict: Accurate** - arXiv:2510.27130, October 2025. Author Srijit Seal confirmed.

### Bib entry: lakhan2025agentic
- **Verdict: Accurate** - Cureus, Vol 17, No 5, May 2025. Author Shaheen E. Lakhan confirmed. DOI correct.

---

## Summary of Issues Found

### Issues Requiring Correction (3)

1. **ChatInvent characterization (Claim 7):** The paper says ChatInvent "mines literature" and "completed a 13-month deployment for literature synthesis." ChatInvent is described in the original paper as a system for "molecular design and synthesis planning," not primarily literature synthesis. The 13-month deployment figure needs verification. **Severity: Medium.** Mischaracterizing a competing paper's scope could undermine credibility with reviewers familiar with the work.

2. **SMILES/stereochemistry overstatement (Claim 28):** "Peptides cannot encode as SMILES without losing stereochemistry" is overstated. SMILES can encode stereochemistry but with significant practical limitations for peptides. **Severity: Low.** Soften the language.

3. **Active learning 30-40% figure (Claim 20):** The specific statistic attributed to Reker 2017 could not be verified. If this is from practitioner experience, it should not be attributed to the citation. **Severity: Low-Medium.** Citation misattribution could be caught by reviewers.

### Issues to Consider Softening (3)

4. **PharmAgents rigid-body docking claim (Claim 10):** Could not verify that PharmAgents specifically uses rigid-body docking. Consider softening.

5. **Morgan/MACCS "no peptide analog" (Claim 29):** Slightly overstated; atom-pair fingerprints exist for peptides, though no standard equivalent to Morgan/MACCS.

6. **Stokes 2020 Cell page numbers (Bib):** There is some ambiguity in the volume/issue/page numbers. Verify against the original.

### All Other Claims Verified as Accurate (39+)

The vast majority of technical claims in the manuscript are accurate and well-supported by the literature. The characterizations of protein language models, agent systems, ML/RL methods, Pareto optimization, peptide challenges, and bioinformatics tools are all technically sound. The bibliography is largely accurate with correct DOIs, PMIDs, and publication details.

---

## Overall Assessment

**Technical accuracy rating: Strong (approximately 90-95% of claims verified as accurate)**

The paper demonstrates deep technical knowledge across multiple domains (PLMs, RL, bioinformatics, multi-objective optimization, peptide chemistry, toxicology). The few issues identified are largely matters of precision in language rather than fundamental errors. The most significant issue is the characterization of ChatInvent's capabilities, which should be corrected to accurately represent the original paper's scope.

The bibliography is well-maintained with correct metadata for the vast majority of entries. The technical arguments are internally consistent and grounded in real methodological challenges.

**Key recommendation:** Address the ChatInvent characterization, soften the SMILES stereochemistry and Morgan fingerprint claims, and verify the active learning statistic attribution. These are straightforward fixes that will strengthen the paper's credibility with technical reviewers.
